Alcon (ALC) Receives a Buy from Credit Suisse

In a report released yesterday, Matt Miksic from Credit Suisse maintained a Buy rating on Alcon (ALCResearch Report), with a price target of $96.00. The company’s shares closed last Thursday at $77.45.

According to TipRanks.com, Miksic is a 5-star analyst with an average return of 16.3% and a 73.1% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Vicarious Surgical, and Johnson & Johnson.

Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $86.55, a 9.4% upside from current levels. In a report issued on February 16, BTIG also maintained a Buy rating on the stock with a $92.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Alcon’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.1 billion and net profit of $2 million. In comparison, last year the company earned revenue of $1.94 billion and had a net profit of $95 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.

Read More on ALC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More